Records containing: HPV Vaccine
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-03-27A Randomized Trial of Digital Interventions to Increase HPV Vaccination Intentions Among Nigerian Caregivers
-
CLINICAL_TRIALS study record update · 2026-01-30A Randomized, Observer-Blind, Placebo-Controlled, Proof-of-Concept Study to Assess the Safety, Tolerability and Immunogenicity of a Bivalent Human Papillomavirus (HPV) Vaccine in 9 and 15 Month Old Infants and Toddlers, 2-5 Year Old Children and an Open Label Single Dose Study in Young Unmarried Females Aged 15-20 Years in Ghana
-
CLINICAL_TRIALS study record update · 2025-10-01Evaluation of a Vaccine Chatbot on HPV Vaccine Confidence and Hesitancy: a Randomized Controlled Trial and Implementation Science Study
-
CLINICAL_TRIALS study record update · 2025-09-29Persistence of Immune Response Six Years After One Dose of 9vHPV Vaccine Among Male and Female Students
-
CLINICAL_TRIALS study record update · 2025-08-24A Multi-site, Open-label Non-inferiority Trial to Assess Immunogenicity of Two Doses of the Nonavalent Human Papillomavirus (HPV) Vaccine Among Children, Adolescents and Young Adults (9-26 Years) Living With HIV vs Three Doses of Nonavalent HPV Vaccine Among HIV Uninfected Young Women (15-26 Years) in Eswatini
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2025-04-25Human Papillomavirus Ends Here: A Multilevel Intervention to Increase Uptake of the HPV Vaccine Among Adolescents
-
CLINICAL_TRIALS study record update · 2025-03-27Immunogenicity of Fractional Dose of the HPV Vaccines
-
CLINICAL_TRIALS study record update · 2025-03-27Immunogenicity of Fractional Dose of the Bivalent and Nonavalent Intradermal HPV Vaccines.
-
CLINICAL_TRIALS study record update · 2024-06-12Evaluation of Vaccine Chatbot on HPV Vaccine Awareness and Vaccination for Middle School Girls in China: a Randomized Controlled Trial and Implementation Science Study
-
CLINICAL_TRIALS study record update · 2024-06-04Adaptation of an HPV Education Resource to Promote HPV Vaccination Among Latino Young Men Who Have Sex With Men in Puerto Rico and Florida -- Proyecto Hombres Previniendo el VPH (Proyecto HPV)
-
CLINICAL_TRIALS study record update · 2024-05-08Evaluating the Feasibility and Effectiveness of a Mock-up Fact-checking Extension to Improve Ability to Debunk HPV Vaccine Misinformation Among Parents of Middle School Girls: A Survey Experiment
-
CLINICAL_TRIALS study record update · 2023-11-18Two Domestic HPV Vaccines (Wozehui ® and Cecolin ®) and Imported HPV Vaccines in Women Aged 13-14 Years Study on Immunogenicity：A Multi-center Cohort Study in China
-
CLINICAL_TRIALS study record update · 2023-10-27Prevalence Study of ENT-related Diseases in Conscripts at the Military Induction Board
-
CLINICAL_TRIALS study record update · 2022-07-25Evaluating the Feasibility of a Mobile Coaching Intervention to Improve HPV Vaccine Delivery
-
CLINICAL_TRIALS study record update · 2021-01-15A Longitudinal Cohort Study to Assess Sustained Immunogenicity up to 48 Months to Quadrivalent Human Papillomavirus Vaccine Among HIV-infected Girls and Boys Age 10-15 Years in Kenya
-
CLINICAL_TRIALS study record update · 2020-08-20State Immunization Information Systems to Improve HPV Vaccination Rates
-
CLINICAL_TRIALS study record update · 2019-11-21Retrospective Cohort Study to Analyze Whether Prophylactic Vaccination Against HPV Can Reduce the Risk of Recurrence in Women Who Have Received an Excisional Therapy for HSIL / CIN2-3. Recurrence is Defined as the Detection of Infection by the Same HPV Genotype for at Least 6-12 Months (Persistent Infection), and / or Cytological Alteration and / or Cervical and / or Vaginal Histological Lesion of Any Grade (SIL / CIN / VaIN) in Patients With Negative Cotest in the First Post Control.